Organon CMO receives 6,447 shares as stock awards vest

Available on EDGAR 11/10/2026 - 04:07 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:06 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Organon & Co. Head of R&D & CMO Ferreira Juan Camilo Arjona reported that 6,447 restricted stock units vested and were distributed as common shares on November 7, 2026. On the same date, 2,314 shares were delivered or withheld for payment of exercise price or tax liability, at a reported $13.87 per share. The derivative RSU position was reported as 0 following the transaction.

Insider Trade Summary

6,447 shares exercised/converted

Exercise 3 txns

Insider Arjona Ferreira Juan Camilo

Role Head of R&D & CMO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F1, F2	6,447	$0.00	$0.00
Exercise	Common Stock	6,447	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	2,314	$13.87	$32K

Holdings After Transaction: Restricted Stock Units — 0 units (Direct); Common Stock — 41,565.477 shares (Direct)

Holdings Before and After: Restricted Stock Units, 6,447 to 0 units (Direct); Common Stock, 37,432.477 to 41,565.477 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.
2. F2. These RSUs vest and are distributed as shares of Organon common stock in three installments: 6,446 shares on November 7, 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026.

Key Figures

RSUs vested and distributed: 6,447 RSUs Common shares acquired: 6,447 shares Shares delivered or withheld: 2,314 shares +2 more

5 metrics

RSUs vested and distributed 6,447 RSUs November 7, 2026 installment

Common shares acquired 6,447 shares Distributed from RSUs on November 7, 2026

Shares delivered or withheld 2,314 shares For payment of exercise price or tax liability on November 7, 2026

Reported per-share price $13.87 per share For the 2,314-share transaction on November 7, 2026

Derivative RSU position following transaction 0 RSUs Reported following the November 7, 2026 transaction

Key Terms

Restricted Stock Units, contingent right, exercise price or tax liability

3 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"a contingent right to receive one share of Organon & Co. common stock"

exercise price or tax liability financial

"payment of exercise price or tax liability by delivering or withholding securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OGN shares did the Head of R&D & CMO receive from RSUs?

Ferreira Juan Camilo Arjona reported that 6,447 restricted stock units vested and were distributed as 6,447 common shares on November 7, 2026.

How many OGN shares were delivered or withheld for the RSU transaction?

2,314 common shares were delivered or withheld for payment of exercise price or tax liability on November 7, 2026, at a reported $13.87 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arjona Ferreira Juan Camilo

(Last) (First) (Middle)

C/O ORGANON &CO.

30 HUDSON STREET, FLOOR 33

(Street)

JERSEY CITY NEW JERSEY 07302

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of R&D & CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2026		M		6,447	A	$0	43,879.477	D
Common Stock	11/07/2026		F		2,314	D	$13.87	41,565.477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	11/07/2026		M			6,447	11/07/2024(2)	11/07/2026	Common Stock	6,447	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

2. These RSUs vest and are distributed as shares of Organon common stock in three installments: 6,446 shares on November 7, 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026.

Remarks:

	/s/ Tarnetta Jones, as Attorney-in-fact for Dr. Juan Camilo Arjona Ferreira	11/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)